- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04076241
Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension
Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment on Exhaled Nitric Oxide Level and Cardiopulmonary Function in Patients With Pulmonary Arterial Hypertension
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pulmonary arterial hypertension (PAH) is characterized by a mean pulmonary arterial pressure of >20 mmHg, measured by right heart catheterization at rest. PAH begins in the small arteries of the pulmonary vasculature and is characterized by increased vasoconstriction. Pulmonary vasodilatation induced by perivascular nerve stimulation usually occurs with nitric oxide (NO). A decrease in the airway wall concentration of NO was detected in patients with PAH. It has been reported that patients with PAH have a mild to moderate decrease in lung volumes associated with disease severity. A decrease in exercise capacity and respiratory muscle strength has been reported in patients with PAH.
Osteopathic Manipulative Therapy (OMT) is a well-known manual therapy approved by World Health Organization. A single-session of OMT was found to increase pulmonary function, inspiratory muscle strength, oxygen saturation, and to reduce dyspnea and fatigue in individuals with severe chronic obstructive pulmonary disease. It has been observed that OMT increases parasympathetic activity and reduces blood pressure in patients with hypertension.
Pranayama breathing is an important component of of yoga. It has been reported that yoga respiratory training increases vagal tone and reduces sympathetic activity, increases vital capacity, controls heart rate and blood pressure, and improves respiratory muscle strength.
No study investigating the effects of adding yoga respiratory training to osteopathic manipulative treatment in patients with PAH was found in the literature. The investigators aimed to explore the effects of a combined intervention consisting of OMT and yoga breathing exercises, as well as OMT alone on exhaled NO level, pulmonary function, respiratory and peripheral muscle strength, and exercise capacity in patients with PAH.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey
- Istanbul University-Cerrahpasa, Cardiology Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pulmonary hypertension patients that are clinically and hemodynamically stable
- Resting mean pulmonary arterial pressure > 20 millimeter of mercury (mmHg) during a right heart catheterization
- Being over 18 years old
- Volunteering to participate in the study and to sign a written informed consent form
- Patients with New York Heart Association (NYHA) functional class I-II-III
- Stable pulmonary hypertension patients that takes medication at least 3 months.
Exclusion Criteria:
- Acute decompensated heart failure
- Unstable angina pectoris
- Recent thoracic or abdominal surgical procedures
- Severe neurological impairments
- Severe cognitive impairment
- Recent syncope
- Using the immune system drugs as a result of organ or tissue transplants
- Fractures within the past six months
- Osteoporosis
- Tumors
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Combined intervention
Combined intervention group consisted of 16 pulmonary arterial hypertension (PAH) patients.
Three different yoga breathing exercises were applied after osteopathic manipulative treatment (OMT).
This combined intervention was applied 2 times a week for a period of 8 weeks with a total of 16 training sessions.
There remained a 3-workday gap between two sessions.
Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
|
The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release.
Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone.
Diaphragm release is used to increase diaphragm movement.
Suboccipital decompression involves traction of the base of the skull.
We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures.
Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration.
Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
Nadishodhana pranayama (Alternate nostril breathing), Ujjayi pranayama (Psychic breath) and Bhramari pranayama (Humming bee breath) were used for the study.
Nadishodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one.
The patients performed 2 sets of 8 breathing cycles with a resting time of 2 minutes between the sets.
Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis.
The patients performed 2 sets of 10 breathing cycles per session with an inspiration:expiration phase as 1:2.
Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils.
The patients applied 2 sets of 10 breathing cycles per session with a respiration rate of 3-4/min.
|
|
Active Comparator: Osteopathic manipulative treatment
OMT group consisted of 16 PAH patients.
Six different OMT techniques were applied 2 times a week for a period of 8 weeks with a total of 16 sessions.
The same osteopathic manipulative treatment techniques applied to combined intervention group were used for this study group.
There remained a 3-workday gap between two sessions.
Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
|
The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release.
Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone.
Diaphragm release is used to increase diaphragm movement.
Suboccipital decompression involves traction of the base of the skull.
We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures.
Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration.
Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
|
|
No Intervention: Control
Control group also consisted of 16 PAH patients and serves as the controls.
No interventions were applied for the patients in this group.
Similar with the patients in other two groups, pharmacological treatment of the patients in this group continued and they were advised for using their medication properly, Patients in this group were also thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline Forced Vital Capacity (FVC), Forced Expiratory Volume in One Second (FEV1) at 8 weeks
Time Frame: Baseline and week 8
|
FVC and FEV1 were recorded in liter (l) by using spirometry (Spiro USB, CareFusion US).
Measurements were performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations.
|
Baseline and week 8
|
|
Change from Baseline Forced Expiratory Volume in One Second/Forced Vital Capacity (FEV1/FVC) at 8 weeks
Time Frame: Baseline and week 8
|
FEV1/FVC ratio (%) was recorded with regards to the highest FEV1 and FVC values measured by spirometry.
|
Baseline and week 8
|
|
Change from Baseline Forced Expiratory Flow at 25-75% of FVC (FEF25-75) at 8 weeks
Time Frame: Baseline and week 8
|
FEF25-75 was recorded in liter/second (l/s) by using spirometry (Spiro USB, CareFusion US).
Measurements were performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations.
|
Baseline and week 8
|
|
Change from Baseline Peak Expiratory Flow (PEF) at 8 weeks
Time Frame: Baseline and week 8
|
PEF was recorded in liter/minute (l/min) by using spirometry (Spiro USB, CareFusion US).
Measurements were performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations.
|
Baseline and week 8
|
|
Change from Baseline FVC%, FEV1%, FEF25-75%, PEF% at 8 weeks
Time Frame: Baseline and week 8
|
FVC%, FEV1%, FEF25-75% and PEF% were recorded as the percentage of predicted values.
|
Baseline and week 8
|
|
Change from Baseline Nitric Oxide Level at 8 weeks
Time Frame: Baseline and week 8
|
Fractional Exhaled Nitric Oxide (FeNO) was measured according to ATS/ERS recommendations with a hand-held, portable device (NObreath, Bedfont, UK).
After inhaling the ambient air for 2-3 seconds until the total lung capacity, the patient is asked to exhale into the device for more than 6 seconds at constant flow rate (50 milliliter/second) without holding breath.
The mean of two technically acceptable values within 10% was recorded in parts per billion (ppb) and maximum six attempts were performed.
|
Baseline and week 8
|
|
Change from Baseline Exercise Capacity at 8 weeks
Time Frame: Baseline and week 8
|
Exercise capacity was measured with the 6 Minute Walk Test (6MWT) according to the ATS guidelines.
The 6 minutes wallking distance (6MWD) was recorded in meters.
Higher scores indicate a better outcome.
|
Baseline and week 8
|
|
Change from Baseline 6MWD% at 8 weeks
Time Frame: Baseline and week 8
|
6MWD% was recorded as the percentage of predicted distances.
Higher scores indicate a better outcome.
|
Baseline and week 8
|
|
Change from Baseline Changes of Perceived Dyspnea and Fatigue at 8 weeks
Time Frame: Baseline and week 8
|
Perceived dyspnea and fatigue were measured before and immediately after 6MWT with modified Borg scale ranging from 0 to 10. Higher scores indicate a worse outcome.
Changes of perceived dyspnea and fatigue were recorded.
|
Baseline and week 8
|
|
Change from Baseline Resting Peripheral Oxygen Saturation (SpO2) at 8 weeks
Time Frame: Baseline and week 8
|
SpO2 was measured by using a pulse oximeter and was recorded as percentage.
|
Baseline and week 8
|
|
Change from Baseline Change of Blood Pressure at 8 weeks
Time Frame: Baseline and week 8
|
Systolic and diastolic blood pressures were measured before and immediately after 6MWT with sphygmomanometer.
Change of systolic blood pressure and change of diastolic blood pressure were recorded.
|
Baseline and week 8
|
|
Change from Baseline Resting Heart Rate at 8 weeks
Time Frame: Baseline and week 8
|
Resting heart rate was measured with a pulse oximeter and was recorded as beats per minute (bpm).
|
Baseline and week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline Respiratory Muscle Strength at 8 weeks
Time Frame: Baseline and week 8
|
MIP and MEP were recorded as cmH2O, as well as MIP% and MEP% were recorded as the percentage of predicted values according to age and gender, as described by Black and Hyatt.
|
Baseline and week 8
|
|
Change from Baseline Peripheral Muscle Strength at 8 weeks
Time Frame: Baseline and week 8
|
Hand grip strength was measured with a hand-held dynamometer bilaterally.
Three measurements on both hands were performed and the highest values were recorded in kilograms.
|
Baseline and week 8
|
Collaborators and Investigators
Investigators
- Principal Investigator: Baha Naci, PhD., Istanbul University - Cerrahpasa (IUC)
- Study Director: Rengin Demir, PhD., Istanbul University - Cerrahpasa (IUC)
- Study Chair: Mehmet Serdar Kucukoglu, MD, Istanbul University - Cerrahpasa (IUC)
Publications and helpful links
General Publications
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available. Erratum In: Am J Respir Crit Care Med. 2016 May 15;193(10):1185.
- Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29. No abstract available.
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available.
- Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis. 1969 May;99(5):696-702. doi: 10.1164/arrd.1969.99.5.696. No abstract available.
- Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grunig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006 Oct 3;114(14):1482-9. doi: 10.1161/CIRCULATIONAHA.106.618397. Epub 2006 Sep 18.
- American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30. doi: 10.1164/rccm.200406-710ST. No abstract available.
- American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002 Aug 15;166(4):518-624. doi: 10.1164/rccm.166.4.518. No abstract available.
- McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28;119(16):2250-94. doi: 10.1161/CIRCULATIONAHA.109.192230. Epub 2009 Mar 30. No abstract available. Erratum In: Circulation. 2009 Jul 14;120(2):e13.
- Ayajiki K, Okamura T, Noda K, Toda N. Functional study on nitroxidergic nerve in isolated dog pulmonary arteries and veins. Jpn J Pharmacol. 2002 Jun;89(2):197-200. doi: 10.1254/jjp.89.197.
- World Health Organization (WHO) Benchmarks for training in traditional/complementary and alternative medicine: benchmarks for training in osteopathy. Geneva: WHO Press; 2010.
- Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005 Aug 1;172(3):352-7. doi: 10.1164/rccm.200412-1684OC. Epub 2005 May 5.
- Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol. 2003 Mar 19;41(6):1028-35. doi: 10.1016/s0735-1097(02)02964-9.
- Desai SA, Channick RN. Exercise in patients with pulmonary arterial hypertension. J Cardiopulm Rehabil Prev. 2008 Jan-Feb;28(1):12-6. doi: 10.1097/01.HCR.0000311502.57022.73. Erratum In: J Cardiopulm Rehabil Prev. 2008 Mar-Apr;28(2):table of contents.
- Kabitz HJ, Bremer HC, Schwoerer A, Sonntag F, Walterspacher S, Walker DJ, Ehlken N, Staehler G, Windisch W, Grunig E. The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension. Lung. 2014 Apr;192(2):321-8. doi: 10.1007/s00408-013-9542-9. Epub 2013 Dec 13.
- Yilmaz Yelvar GD, Cirak Y, Demir YP, Dalkilinc M, Bozkurt B. Immediate effect of manual therapy on respiratory functions and inspiratory muscle strength in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016 Jun 20;11:1353-7. doi: 10.2147/COPD.S107408. eCollection 2016.
- Curi ACC, Maior Alves AS, Silva JG. Cardiac autonomic response after cranial technique of the fourth ventricle (cv4) compression in systemic hypertensive subjects. J Bodyw Mov Ther. 2018 Jul;22(3):666-672. doi: 10.1016/j.jbmt.2017.11.013. Epub 2017 Dec 9.
- Nayar HS, Mathur RM, Kumar RS. Effects of yogic exercises on human physical efficiency. Indian J Med Res. 1975 Oct;63(10):1369-76. No abstract available.
- Singh S, Gaurav V, Parkash V. Effects of a 6-week nadi-shodhana pranayama training on cardio-pulmonary parameters. J. Phys. Educ. Sport Manag. 2: 44-47, 2011.
- Garg S, Chandla SS. Effect of nadi shodhan pranayama on pulmonary functions. Int J Health Sci Res. 6: 192-196, 2016.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018/0180
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Inhibikase TherapeuticsNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
-
University of Sao Paulo General HospitalRecruitingPulmonary Arterial Hypertension (PAH)Brazil
-
University Hospital, BrestNot yet recruitingPulmonary Arterial Hypertension (PAH)France
-
Shanghai Zhongshan HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
Clinical Trials on Osteopathic manipulative treatment
-
Ecole d'ostéopathie de ParisUniversity of Paris 5 - Rene DescartesCompleted
-
Nantes University HospitalCompletedBreast Feeding, ExclusiveFrance
-
Good Samaritan Hospital Medical Center, New YorkUnknownHeadacheUnited States
-
New York Institute of TechnologyCompletedDistorted; Balance | Post-Concussion SymptomsUnited States
-
New York Institute of TechnologyRecruitingParkinson's Disease | ConstipationUnited States
-
Come CollaborationUniversity of ChietiCompleted
-
New York Institute of TechnologyWithdrawn
-
University of California, San DiegoEnrolling by invitation
-
Des Moines UniversityCompletedOsteopathy in Diseases Classified ElsewhereUnited States